- Home
- PVLA vs BCLI Comparison
PVLA vs BCLI Comparison
Compare PVLA & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVLA
- BCLI
- Stock Information
- Founded
- PVLA 2015
- BCLI 2000
- Country
- PVLA United States
- BCLI United States
- Employees
- PVLA N/A
- BCLI N/A
- Industry
- PVLA Biotechnology: Pharmaceutical Preparations
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PVLA Health Care
- BCLI Health Care
- Exchange
- PVLA Nasdaq
- BCLI Nasdaq
- Market Cap
- PVLA 15.9M
- BCLI 13.5M
- IPO Year
- PVLA N/A
- BCLI N/A
- Fundamental
- Price
- PVLA $13.15
- BCLI $2.13
- Analyst Decision
- PVLA Strong Buy
- BCLI Strong Buy
- Analyst Count
- PVLA 1
- BCLI 1
- Target Price
- PVLA $38.00
- BCLI $30.00
- AVG Volume (30 Days)
- PVLA 39.6K
- BCLI 83.9K
- Earning Date
- PVLA 02-15-2025
- BCLI 11-14-2024
- Dividend Yield
- PVLA N/A
- BCLI N/A
- EPS Growth
- PVLA N/A
- BCLI N/A
- EPS
- PVLA N/A
- BCLI N/A
- Revenue
- PVLA N/A
- BCLI N/A
- Revenue This Year
- PVLA N/A
- BCLI N/A
- Revenue Next Year
- PVLA N/A
- BCLI N/A
- P/E Ratio
- PVLA N/A
- BCLI N/A
- Revenue Growth
- PVLA N/A
- BCLI N/A
- 52 Week Low
- PVLA $6.20
- BCLI $1.05
- 52 Week High
- PVLA $22.32
- BCLI $11.85
- Technical
- Relative Strength Index (RSI)
- PVLA N/A
- BCLI 52.92
- Support Level
- PVLA N/A
- BCLI $1.86
- Resistance Level
- PVLA N/A
- BCLI $2.33
- Average True Range (ATR)
- PVLA 0.00
- BCLI 0.18
- MACD
- PVLA 0.00
- BCLI -0.02
- Stochastic Oscillator
- PVLA 0.00
- BCLI 51.92
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.